Skip to main content
ScinoPharm Taiwan, Ltd. logo

ScinoPharm Taiwan, Ltd. — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,191 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1789

About ScinoPharm Taiwan, Ltd.

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
115年第1季財務報告書 — 202601_1789_AI1.pdf
Interim / Quarterly Report Classification · 93% confidence The document is titled “合併財務報告暨會計師核閱報告 民國115年及114年第一季” and contains full consolidated interim financial statements (balance sheet, income statement, cash flows, equity changes, notes) for Q1 (a period shorter than a fiscal year) along with an auditor’s review report. This is not just a notice or summary, but the complete interim financial report prepared under IFRS 34 “Interim Financial Reporting.” Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 85% confidence The document is titled “115年1季申報作業” (Q1 filing operations) on the Taiwan public information observatory and contains substantive financial data (equity-method investment balances and profit/loss amounts) for the first quarter. This is part of the company’s interim/quarterly financial disclosures rather than a brief announcement or an Excel supplement. Therefore it is classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-13 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 82% confidence The document is a standalone regulatory compliance disclosure showing the company’s Mainland China investment details (investment amounts, shareholding ratios, approved limits, etc.) prepared for the Taiwan Public Information Observatory (“公開資訊觀測站”). It does not constitute a full quarterly or annual report, nor an earnings release, board change, M&A, or other specialized category. It is a specific compliance filing, best fitting the fallback category “Regulatory Filings (RNS).”
2026-05-13 Chinese
115年04月內部人持股異動(事後)
Regulatory Filings
2026-05-06 Chinese
115年04月董事會成員及持股
Regulatory Filings
2026-05-06 Chinese
公告本公司法人董事改派代表人
Regulatory Filings
2026-04-30 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.